# US 2022/0064105 A1 · Crystalline edg-2 receptor antagonist and methods of making

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064105 A1
- Document ID: US20220064105A1
- Status: Published application
- Kind: A1
- Application number: 17/463,369
- Filed: 2021-08-31
- Published: 2022-03-03
- Earliest claimed: 2020-08-31
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Josef PERNERSTORFER; William ROCCO; Jason BRITTAIN
- Web page: https://patentgrep.com/patent/US20220064105A1

## CPC

- C07C 235/54: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07C 231/24: Separation; Purification
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Described herein are crystalline forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid and methods of making the same. Such forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with an EDG-2 receptor antagonist compound.

## Claims

### Claim 1

Crystalline Form 1 of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I), characterized as having an X-ray powder diffraction (XRPD) pattern with peaks at 5.2±0.2° 2-Theta, 9.0±0.2° 2-Theta, 14.4±0.2° 2-Theta, and 17.7±0.2° 2-Theta, as measured using Cu (Kα) radiation.

### Claim 2

Crystalline Form 1 of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I), characterized as having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 1, as measured using Cu (Kα) radiation.

### Claim 3 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I is further characterized as having a Fourier Transform IR Spectroscopy (FTIR) pattern with a peak at about 1739.6 cm−1.

### Claim 4 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I is further characterized as having a Solid State 13Carbon Nuclear Magnetic Resonance (ssNMR) spectrum substantially the same as shown in FIG. 4.

### Claim 5 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I is further characterized as having a Solid State 13Carbon Nuclear Magnetic Resonance (ssNMR) spectrum characterized by resonances (δc) at 23.35, 124.43, 126.78, 127.42, and 136.47 ppm.

### Claim 6 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I is further characterized as having a Differential Scanning calorimetry (DSC) thermogram substantially the same as shown in FIG. 2.

### Claim 7 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I is further characterized as having a Differential Scanning calorimetry (DSC) thermogram with three endothermic events having: an onset at about 198.5° C. and a peak at about 200.4° C.; an onset at about 204.8° C. and a peak at about 205.8° C.; and an onset at about 213.9° C. and a peak at about 216.3° C.

### Claim 8 (depends on 2)

The crystalline form of claim 2, wherein the crystalline Form 1 of Compound I is further characterized as having a Fourier Transform IR Spectroscopy (FTIR) pattern with a peak at about 1739.6 cm−1.

### Claim 9 (depends on 2)

The crystalline form of claim 2, wherein the crystalline Form 1 of Compound I is further characterized as having a Solid State 13Carbon Nuclear Magnetic Resonance (ssNMR) spectrum substantially the same as shown in FIG. 4.

### Claim 10 (depends on 2)

The crystalline form of claim 2, wherein the crystalline Form 1 of Compound I is further characterized as having a Solid State 13Carbon Nuclear Magnetic Resonance (ssNMR) spectrum characterized by resonances (δc) at 23.35, 124.43, 126.78, 127.42, and 136.47 ppm.

### Claim 11 (depends on 2)

The crystalline form of claim 2, wherein the crystalline Form 1 of Compound I is further characterized as having a Differential Scanning calorimetry (DSC) thermogram substantially the same as shown in FIG. 2.

### Claim 12 (depends on 2)

The crystalline form of claim 2, wherein the crystalline Form 1 of Compound I is further characterized as having a Differential Scanning calorimetry (DSC) thermogram with three endothermic events having: an onset at about 198.5° C. and a peak at about 200.4° C.; an onset at about 204.8° C. and a peak at about 205.8° C.; and an onset at about 213.9° C. and a peak at about 216.3° C.

### Claim 13 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I has unit cell parameters substantially equal to the following at 293 K:
Crystal System
triclinic
Space Group
P-1; Z = 2
a (Å)
6.521(6)
b (Å)
10.548(9)
c (Å)
17.453(15)
α (°)
104.080(16)
β (°)
92.430(16)
γ (°)
101.081(17)
V (Å3)
1137.6(17)
Calculated Density (Mg/m3)
1.301
Unique Reflections
4753

### Claim 14 (depends on 2)

The crystalline form of claim 2, wherein the crystalline Form 1 of Compound I has unit cell parameters substantially equal to the following at 293 K:
Crystal System
triclinic
Space Group
P-1; Z = 2
a (Å)
6.521(6)
b (Å)
10.548(9)
c (Å)
17.453(15)
α (°)
104.080(16)
β (°)
92.430(16)
γ (°)
101.081(17)
V (Å3)
1137.6(17)
Calculated Density (Mg/m3)
1.301
Unique Reflections
4753

### Claim 15 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I is anhydrous.

### Claim 16 (depends on 2)

The crystalline form of claim 2, wherein the crystalline Form 1 of Compound I is anhydrous.

### Claim 17 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I is substantially free of crystalline Form 2 of Compound I.

### Claim 18 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form 1 of Compound I comprises less than 1% w/w of crystalline Form 2 of Compound I.

### Claim 19 (depends on 2)

The crystalline form of claim 2, wherein the crystalline Form 1 of Compound I is substantially free of crystalline Form 2 of Compound I.

### Claim 20 (depends on 3)

The crystalline form of claim 3, wherein the crystalline Form 1 of Compound I comprises less than 1% w/w of crystalline Form 2 of Compound I.

### Claim 21

Amorphous phase of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I) characterized as having: an X-ray powder diffraction (XRPD) pattern showing a lack of crystallinity, and a Solid State 13Carbon Nuclear Magnetic Resonance (ssNMR) spectrum substantially the same as shown in FIG. 16.

### Claim 22

A pharmaceutical composition comprising crystalline Form 1 of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I), and at least one pharmaceutically acceptable excipient;
wherein crystalline Form 1 of Compound I is characterized as having an X-ray powder diffraction (XRPD) pattern with peaks at 5.2±0.2° 2-Theta, 9.0±0.2° 2-Theta, 14.4±0.2° 2-Theta, and 17.7±0.2° 2-Theta, as measured using Cu (Kα) radiation; and
wherein the pharmaceutical composition is in the form of a solid form pharmaceutical composition.

### Claim 23 (depends on 22)

The pharmaceutical composition of claim 22, wherein the pharmaceutical composition is in the form of a tablet, a pill, or a capsule.

### Claim 24 (depends on 22)

The pharmaceutical composition of claim 22, wherein the pharmaceutical composition is in the form of a tablet and comprises about 50 mg to about 300 mg of crystalline Form 1 of Compound I.

### Claim 25 (depends on 22)

The pharmaceutical composition of claim 22, wherein the pharmaceutical composition is in the form of a tablet and comprises about 150 mg of crystalline Form 1 of Compound I.

### Claim 26 (depends on 22)

The pharmaceutical composition of claim 22, wherein the crystalline Form 1 of Compound I is substantially free of crystalline Form 2 of Compound I.

### Claim 27 (depends on 22)

The pharmaceutical composition of claim 22, wherein the crystalline Form 1 of Compound I comprises less than 1% w/w of crystalline Form 2 of Compound I.
